Abstract: Mesothelioma growth inhibitory effect of standard cisplatin-pemetrexed concomitant therapy is potentiated by combination with an anti-CD26 antibody. A high therapeutic effect and excellent safety is obtained by the concomitant use of an anti-CD26 antibody and gemcitabine. By conjugating an anti-CD26 antibody (YS110) with triptolide via a divalent cross-linking agent for concomitant therapy using the anti-CD26 antibody, a novel antibody-drug conjugate (Y-TR1) very highly effective for CD26-positive malignant mesothelioma cells has been successfully obtained.

Abstract: A phenylphthalimide derivative represented by the following general formula is provided as a phenylphthalimide derivative useful against various cancers including multiple myeloma, wherein R1 is a group containing PEG or a hydroxy C1-5 alkoxy group binding to position 4 or position 5, R2 is an amino group at position 6, and R3 and R4 are each independently a hydrogen atom, an alkyl group, an aryl group, an aralkyl group, or an aryloxy group.

Abstract: Mesothelioma growth inhibitory effect of standard cisplatin-pemetrexed concomitant therapy is potentiated by combination with an anti-CD26 antibody. A high therapeutic effect and excellent safety is obtained by the concomitant use of an anti-CD26 antibody and gemcitabine. By conjugating an anti-CD26 antibody (YS110) with triptolide via a divalent cross-linking agent for concomitant therapy using the anti-CD26 antibody, a novel antibody-drug conjugate (Y-TR1) very highly effective for CD26-positive malignant mesothelioma cells has been successfully obtained.

Abstract: It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.

Abstract: A server system (9) in provided with: a first server (91) that operates in an active mode; and a plurality of second servers (92) that operate in a standby mode as a standby server for the first server (91), wherein the plurality of second servers (92) includes a location information control unit (921) that, in response to an access from a client, transmits a location information which indicates a location of the client to the first server (91), and a switching processing unit (922) that, upon reception of a switching instruction information transmitted from the first server (91), performs switching so as to cause the second server itself to change its mode from the standby mode to the active mode, and wherein the first server (91) includes a switching destination determination unit (911) that, on the basis of the location information transmitted by the second server (92), determines, as a switching destination, a second server (92) which constitutes the plurality of second servers (92) and which exists at

Abstract: It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.

Abstract: A server system (9) in provided with: a first server (91) that operates in an active mode; and a plurality of second servers (92) that operate in a standby mode as a standby server for the first server (91), wherein the plurality of second servers (92) includes a location information control unit (921) that, in response to an access from a client, transmits a location information which indicates a location of the client to the first server (91), and a switching processing unit (922) that, upon reception of a switching instruction information transmitted from the first server (91), performs switching so as to cause the second server itself to change its mode from the standby mode to the active mode, and wherein the first server (91) includes a switching destination determination unit (911) that, on the basis of the location information transmitted by the second server (92), determines, as a switching destination, a second server (92) which constitutes the plurality of second servers (92) and which exists at a